medigraphic.com
SPANISH

Revista Médica del Instituto Mexicano del Seguro Social

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2006, Number S2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (S2)

Positive autoantibody: does it have any clinical importance?

Mávil LLC
Full text How to cite this article

Language: Spanish
References: 9
Page: 25-30
PDF size: 90.10 Kb.


Key words:

autoantibody, hemolitic anaemia, autoimmune, cold aglutinin, warm autoantibody.

ABSTRACT

In immunohematology, the term ‘autoantibody’ is used for any antibody which reacts with a corresponding antigen on the subject’s own red cells if the reaction takes place only in vitro and whether or not any pathological effects are produce in vivo. The autoantibodies may be classified as harmful or harmless, according to whether or not they are associated with red cell destruction. Most red cell autoantibodies can be classified as cold or warm. The distinction between harmless and harmful cold antibodies depends solely on the maximum temperature at which they are active. Harmful cold autoantibodies are those associated with Cold Agglutinin Syndrome and Paroxysmal Cold Hemoglobinuria. The harmful warm autoantibodies reacting as well, or better, at 37 °C, are found in about 80 % of all cases of AIHA. The AIHA associated with warm autoantibodies in the following cases: when the patient has been recently transfused, the patient is receiving any drugs, the patient has received a marrow or an organ transplant and hemolytic disease of newborn. The associated antibodies in warm AIHA often show an association with Rh system and unusual specificities: Kell system, Kidd system and Duffy system.


REFERENCES

  1. Denys P, van den Broucke J. Anémie Hémolytique acquise et réaction de Coombs. Arch Franc Pédiatr 1947;4:205.

  2. Kuhns WJ, Wagley PF. Hemolytic anemia associated with atypical hemaglutinins. Ann Intern Med 1949;30:408.

  3. Race RR, Sanger R, Selwyn JG. Possible deletion in human Rh chromosome: A serological and genetical study. Br J Exp Pathol 1951;32:124.

  4. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. Tenth edition. United Kingdom: Blackwell Science; 1997. p. 284-309.

  5. Petz LD, Garraty G. Immune hemolytic anemias. Second Edition. United States of America: Churchil Livingstone; 2004. p. 261-396.

  6. Brecher ME. Technical manual. Fourteenth edition. Bethesda, USA: AABB Press; 2003. p. 419-445.

  7. Bryant NJ. An introduction to immunohematology. Third edition. United States of America: W.B. Sanders Company; 1994. p. 277-285.

  8. Pampee PY, Alison U, Elbert T, Doug ML, Lawrence TG. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004;44(1):67-72.

  9. Zumberg MC, Procter JL, Lottenberg R, Kitchens CS, Klein HG. Autoantibody formation in the alloimmunized red blood cell recipient: Clinical and laboratory implications. Arch Inter Med 2001;161:285-290.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Med Inst Mex Seguro Soc. 2006;44